ARS Pharmaceuticals (SPRY) Equity Ratio (2021 - 2025)
Historic Equity Ratio for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to 0.4.
- ARS Pharmaceuticals' Equity Ratio fell 5711.74% to 0.4 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.4, marking a year-over-year decrease of 5711.74%. This contributed to the annual value of 0.73 for FY2024, which is 2610.06% down from last year.
- Latest data reveals that ARS Pharmaceuticals reported Equity Ratio of 0.4 as of Q3 2025, which was down 5711.74% from 0.61 recorded in Q2 2025.
- In the past 5 years, ARS Pharmaceuticals' Equity Ratio registered a high of 0.99 during Q4 2023, and its lowest value of 0.51 during Q4 2021.
- Its 5-year average for Equity Ratio is 0.81, with a median of 0.95 in 2021.
- As far as peak fluctuations go, ARS Pharmaceuticals' Equity Ratio soared by 29053.85% in 2022, and later plummeted by 5711.74% in 2025.
- ARS Pharmaceuticals' Equity Ratio (Quarter) stood at 0.51 in 2021, then surged by 290.54% to 0.97 in 2022, then grew by 2.06% to 0.99 in 2023, then dropped by 26.1% to 0.73 in 2024, then plummeted by 45.84% to 0.4 in 2025.
- Its Equity Ratio was 0.4 in Q3 2025, compared to 0.61 in Q2 2025 and 0.7 in Q1 2025.